PDCD1 and sarcopenia: We conducted a retrospective study to investigate the association of sarcopenia and inflammatory and nutritional biomarkers with treatment outcomes, including long-term responses to PD-1 inhibitors, in patients with advanced mUC who received previous chemotherapy.